MT-ND6
ENSG00000198695
Target class
Enzyme
Chromosome
Mitochondrial
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- MT-ND6
- Gene name
- Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6
- Gene symbol
- MT-ND6
- Previous gene symbols
- MTND6
- Protein name
- NADH-ubiquinone oxidoreductase chain 6 (EC 7.1.1.2) (NADH dehydrogenase subunit 6)
- NAD6
- ND6
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase core subunits|Mitochondrially encoded protein coding genes
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Highest tissue expression
- 12,413.2
- Tissue specificity (Gini)
- 0.285
- Tissue specificity (tau)
- 0.514
- KEGG gene identifiers
- hsa:4541
- Protein interaction confidence
- 0.930767
- Protein interaction partners
- 86
- R-HSA-5419276
- R-HSA-611105
- R-HSA-6799198
- R-HSA-9837999
- End position
- 14673
- Start position
- 14149
- Chromosome
- Mitochondrial
- Strand
- Reverse
- Mitochondrion inner membrane
- Multi-pass membrane protein .
- Tissue specificity (tau)
- 0.514493
- Expression inequality (Gini)
- 0.284763
Expression in transcripts per million
- Fallopian Tube
- 12,413.2
- Brain - Putamen (basal ganglia)
- 12,166
- Muscle - Skeletal
- 11,686.1
- Brain - Caudate (basal ganglia)
- 11,516.6
- Brain - Nucleus accumbens (basal ganglia)
- 10,239.1
Expression in transcripts per million
- Fallopian Tube12,413.2
- Brain - Putamen (basal ganglia)12,166
- Muscle - Skeletal11,686.1
- Brain - Caudate (basal ganglia)11,516.6
- Brain - Nucleus accumbens (basal ganglia)10,239.1
- Heart - Left Ventricle10,093.8
- Small Intestine - Terminal Ileum9,764.49
- Brain - Amygdala9,631.77
- Stomach9,628.75
- Brain - Hypothalamus9,606.64
- Brain - Hippocampus9,409.32
- Heart - Atrial Appendage9,307.78
- Skin - Not Sun Exposed (Suprapubic)8,919.46
- Brain - Substantia nigra8,547.19
- Brain - Anterior cingulate cortex (BA24)8,319.14
- Bladder8,275.2
- Esophagus - Gastroesophageal Junction8,228.02
- Esophagus - Muscularis8,139.34
- Skin - Sun Exposed (Lower leg)8,113.22
- Brain - Cortex7,361.48
- Brain - Frontal Cortex (BA9)6,904.07
- Brain - Spinal cord (cervical c-1)6,903.48
- Adrenal Gland6,637.79
- Colon - Transverse6,551.87
- Artery - Aorta6,374.49
And 29 more, listed on the interactive page.
- GO:0006120
- GO:0032981
- GO:0005739
- GO:0005743
Molecular functions
- GO:0008137
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor